UNIGE document Scientific Article
previous document  unige:81141  next document
add to browser collection

Analogues du GLP-1 versus inhibiteurs du SGLT-2 pour les diabétiques de type 2 obèses

Marques, Ana Rita Forte
Published in Revue médicale suisse. 2015, vol. 11, no. 477, p. 1227-1233
Abstract Who never had a type 2 obese diabetic patient, treated by several oral antidiabetic drugs and insulin, with consequent weight gain associated with the therapeutic escalation and uncontrolled diabetes? The arrival of GLP-1 agonists and SGLT-2 inhibitors allows to reevaluate the management of these patients, with their favorable effects on glycemic control, weight and the risk of hypoglycemia and their complementary mechanisms to conventional treatments. The vicious cycle of weight gain and increased need of insulin is limited. The choice between these two molecules must be based on several factors (glycemic target, weight, comorbidities, route of administration, side effects, etc.), and the balanced enthusiasm of these new treatments with the insufficient data regarding their long-term safety and their impact on micro- and macrovascular complications.
Keywords Diabetes Mellitus, Type 2/complications/drug therapyDipeptidyl-Peptidase IV Inhibitors/therapeutic useGlucagon-Like Peptide 1/analogs & derivativesHumansHypoglycemic Agents/therapeutic useIncretins/therapeutic useObesity/complications/drug therapyPractice Guidelines as TopicReceptors, Glucagon/agonistsSodium-Glucose Transporter 2/antagonists & inhibitors
PMID: 26211282
Full text
Article (Published version) (1.7 MB) - document accessible for UNIGE members only Limited access to UNIGE
Research group Diabète et régulation des gènes (36)
(ISO format)
MARQUES, Ana Rita Forte et al. Analogues du GLP-1 versus inhibiteurs du SGLT-2 pour les diabétiques de type 2 obèses. In: Revue médicale suisse, 2015, vol. 11, n° 477, p. 1227-1233. https://archive-ouverte.unige.ch/unige:81141

284 hits

1 download


Deposited on : 2016-03-01

Export document
Format :
Citation style :